Storia in 2 fonti

WuXi Bio signs manufacturing deal with Viridian as Biosecure threat continues to erode

WuXi Biologics has secured a five-year contract with Viridian Therapeutics to manufacture and supply commercial batches of its monoclonal antibody veligrotug.

Raccontata da

endpoints.news

fiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo3 mesi fa

WuXi Bio signs manufacturing deal with Viridian as Biosecure threat continues to erode

WuXi Biologics has secured a five-year contract with Viridian Therapeutics to manufacture and supply commercial batches of its monoclonal antibody veligrotug.

originale

fiercepharma.com3 mesi fa

Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal

Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a | Viridian aims to challenge Amgen in a blockbuster market, and it's now tapped Chinese CDMO…

Leggi questa versione → originale

Timeline cronologica

mercoledì 27 maggio 2026·endpoints.news
WuXi Bio signs manufacturing deal with Viridian as Biosecure threat continues to erode
WuXi Biologics has secured a five-year contract with Viridian Therapeutics to manufacture and supply commercial batches of its monoclonal antibody veligrotug.
mercoledì 27 maggio 2026·fiercepharma.com
Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a | Viridian aims to challenge Amgen in a blockbuster…